## Thomson Reuters 2014 Citation Laureates: Their Impact on the World

Chemistry



Physics







specifically tailored chemical properties, for adhesives, and in drug delivery and



that offer large internal surface area for delivering



01010101010 010101010

Accelerated the speed of computing

Ramamoorthy Ramesh





storage and power other electronic devices

Peidong Yang



optical properties: from generating lasers to





Annually, Thomson Reuters analysts from IP & Science study scientific literature citation data to identify scientists whose work is worthy of recognition with a Nobel Prize. These individuals are of "Nobel Class," producing highly cited papers, often at levels exceeding 1,000 citations, and are typically authors of multiple highly cited papers.

The Thomson Reuters Citation Laureates have been cited so often in the last two or more decades that they typically rank in the top 0.1% by citations in their research areas. Our top picks for 2014 can be found at sciencewatch.com/nobel. And, the technologies they've influenced are shown in this infographic.



Medicine



**Economics** 



James E. Darnell Robert G. Roeder Robert Tjian



Insights into the actions and regulation of genes promise improved treatment for diabetes and other diseases

David Julius



Understanding the molecular workings of how we perceive temperature, leading to advances in pain management



Clarifying how specific genetic variations link to disease — knowledge that is improving diagnosis and treatment











Creative Destruction: innovation & transformation constantly alter the economic and business landscape to the advantage of those capable of adapting





economic activity is

"embedded" within social
relationships and social
networks, enabling complex
& consequential economic
interactions

# **SCIENCE**WATCH

HOME SCI-BYTES CITATION LAUREATES GLOBAL RESEARCH REPORTS ABOUT SCIENCEWATCH

### Search: Q

### **MEDICINE**

# FOR THEIR DISCOVERY OF LARGE-SCALE COPY NUMBER VARIATION AND ITS ASSOCIATION WITH SPECIFIC DISEASES



Michael H. Wigler
Professor and Head, Mammalian Cell
Genetics Section, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY USA



Charles Lee
Professor and Scientific Director, Jackson
Laboratory for Genomic Medicine,
Farmington, CT USA



Stephen W. Scherer
Senior Scientist and Director,
The Centre for Applied
Genomics, The Hospital for
Sick Children; Professor and
Director, McLaughlin Centre,
University of Toronto, Toronto,
ON CANADA

### **SCIENCE WATCH**

TRACKING TRENDS AND PERFORMANCE IN RESEARCH SINCE 1989

ENTER YOUR EMAIL ADDRESS TO SUBSCRIBE

SUBMIT

CHECK THIS BOX TO OPT IN TO RECEIVE INFORMATION FROM US (YOU CAN UNSUBSCRIBE AT ANY TIME)

#### **ESSAY**

### GENOMIC VARIATION AND DISEASE

The publication of the first drafts of the human genome led many scientists to proclaim that the difference in genetic sequence between any two humans was around 1%. The normal genome was assumed to be 99% identical in all humans, and the differences—underlying all the differences not only in simple things like eye color but also susceptibility to diseases—was down to around 3 million single-nucleotide polymorphisms, or SNPs. Lee and Scherer together and Wigler independently blew this assumption apart.

In 2004, shortly after publication of the human genome, Scherer and Lee showed that the human genome contained what they described as "large-scale variation." Earlier that year, Wigler had described "large-scale copy number variation." Both groups had found that there are large areas of the genome where long stretches, often encompassing several adjacent genes, are either duplicated or deleted. These differences between genomes are now called copy number variants (CNVs). Far from genomes being 99% identical, CNVs cover around 12–13% of the genome and about 2,900 genes, roughly one in ten of all known genes. CNVs tend to be stable and inherited from the parents, although they can also arise spontaneously, and identical twins may differ in copy number variants.

Although most CNVs do not seem to be associated with disease, some are. Scherer and Wigler have both shown an association between CNVs and autism spectrum diseases, and CNVs have also been identified in schizophrenia, systemic lupus erythematosus, some cancers, and even reduced susceptibility to HIV infection. The severity of diseases such as lupus and muscular dystrophy has been linked to differences in the number of copies of the DNA sequences in question.

While the role of CNVs in disease may have driven much of the research, evolutionary biologists have also taken a keen interest, because gene duplication (and most CNVs seem to be duplications rather than deletions) "frees" genes to evolve in different directions. If an organism has but a single copy of a gene, then changes to that gene might well be harmful. If, however, there are multiple copies, then one copy can keep on performing the original function while others are under less constraint and can evolve new kinds of functionality. Many genes belong to families that could have arisen in this way.

Quite apart from their role in disease and evolution, copy number variants raise another fundamental question. If so much of the genome may differ between two individuals, much of it with no obvious consequences, what does it mean even to refer to the "normal" genome?

Commentary on the Medicine Laureates written by Jeremy Cherfas, Biology correspondent, ScienceWatch. A former editor at New Scientist, Dr. Cherfas is a science writer based in Rome, Italy.